Greuter Marjolein Je, Schouten Charlotte S, Castelijns Jonas A, de Graaf Pim, Comans Emile Fi, Hoekstra Otto S, de Bree Remco, Coupé Veerle Mh
Department of Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, MF F-wing ST, 1007, MB, Amsterdam, the Netherlands.
Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, PO Box 7057, 1007, MB, Amsterdam, the Netherlands.
BMC Cancer. 2017 Apr 11;17(1):256. doi: 10.1186/s12885-017-3254-0.
Considerable variation exists in diagnostic tests used for local response evaluation after chemoradiation in patients with advanced oropharyngeal cancer. The yield of invasive examination under general anesthesia (EUA) with biopsies in all patients is low and it may induce substantial morbidity. We explored four response evaluation strategies to detect local residual disease in terms of diagnostic accuracy and cost-effectiveness.
We built a decision-analytic model using trial data of forty-six patients and scientific literature. We estimated for four strategies the proportion of correct diagnoses, costs concerning diagnostic instruments and the proportion of unnecessary EUA indications. Besides a reference strategy, i.e. EUA for all patients, we considered three imaging strategies consisting of FDG-PET-CT, diffusion-weighted MRI (DW-MRI), or both FDG-PET-CT and DW-MRI followed by EUA after a positive test. The impact of uncertainty was assessed in sensitivity analyses.
The EUA strategy led to 96% correct diagnoses. Expected costs were €468 per patient whereas 89% of EUA indications were unnecessary. The DW-MRI strategy was the least costly strategy, but also led to the lowest proportion of correct diagnoses, i.e. 93%. The PET-CT strategy and combined imaging strategy were dominated by the EUA strategy due to respectively a smaller or equal proportion of correct diagnoses, at higher costs. However, the combination of PET-CT and DW-MRI had the highest sensitivity. All imaging strategies considerably reduced (unnecessary) EUA indications and its associated burden compared to the EUA strategy.
Because the combined PET-CT and DW-MRI strategy costs only an additional €927 per patient, it is preferred over immediate EUA since it reaches the same diagnostic accuracy in detecting local residual disease while leading to substantially less unnecessary EUA indications. However, if healthcare resources are limited, DW-MRI is the strategy of choice because of lower costs while still providing a large reduction in unnecessary EUA indications.
晚期口咽癌患者在放化疗后用于局部反应评估的诊断测试存在很大差异。对所有患者进行全身麻醉下的侵入性检查(EUA)并活检的阳性率较低,且可能引发严重并发症。我们探讨了四种反应评估策略,以检测局部残留疾病的诊断准确性和成本效益。
我们使用46例患者的试验数据和科学文献建立了一个决策分析模型。我们估计了四种策略的正确诊断比例、诊断仪器成本以及不必要的EUA指征比例。除了一种参考策略,即对所有患者进行EUA,我们还考虑了三种成像策略,包括FDG-PET-CT、弥散加权MRI(DW-MRI),或FDG-PET-CT和DW-MRI两者,阳性测试后进行EUA。在敏感性分析中评估了不确定性的影响。
EUA策略导致96%的正确诊断。预期成本为每位患者468欧元,而89%的EUA指征是不必要的。DW-MRI策略是成本最低的策略,但正确诊断比例也最低,即93%。PET-CT策略和联合成像策略因正确诊断比例分别较小或相等但成本较高,而被EUA策略主导。然而,PET-CT和DW-MRI的组合具有最高的敏感性。与EUA策略相比,所有成像策略都显著减少了(不必要的)EUA指征及其相关负担。
由于PET-CT和DW-MRI联合策略每位患者仅额外花费927欧元,因此它比立即进行EUA更可取,因为它在检测局部残留疾病方面达到了相同的诊断准确性,同时导致不必要的EUA指征大幅减少。然而,如果医疗资源有限,DW-MRI是首选策略,因为成本较低,同时仍能大幅减少不必要的EUA指征。